TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel ...

Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, tod ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.

Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics ...

Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

A live webcast of each presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following each live presentation, a replay of the webcast will be available ...

As of Wednesday, February 25, CytomX Therapeutics, Inc.’s CTMX share price has surged by 7.44%, which has investors questioning if this is right time to sell.

We grew sales across all income cohorts in Q4,’ the pizza chain said, even as competitors struggled with lower-income consumers ...

Creative Biolabs, a leader in viral vector engineering and immunotherapy solutions, has announced the expansion of its ...